Literature DB >> 34159439

Endocrine hypertension secondary to adrenal tumors: clinical course and predictive factors of clinical remission.

Uriel Clemente-Gutiérrez1, Rafael H Pérez-Soto1, Juan D Hernández-Acevedo1, Nicole M Iñiguez-Ariza2, Enrique Casanueva-Pérez1, Juan Pablo Pantoja-Millán1, Mauricio Sierra-Salazar1, Miguel F Herrera1, David Velázquez-Fernández3.   

Abstract

PURPOSE: Endocrinopathies constitute ~ 10% of secondary hypertension (SH) etiologies. Primary aldosteronism, pheochromocytoma (PHEO), and Cushing's syndrome are common causes. Early identification and treatment result in resolution/improvement of SH. The aim of this study was to characterize the clinical course, outcomes, and remission-associated prognostic factors of SH related to adrenal tumors.
METHODS: Retrospective cohort study including patients with SH who underwent adrenalectomy from 2000 to 2019. Postoperative outcomes were analyzed. Remission was defined as normalization of blood pressure without drug use.
RESULTS: Eighty-three patients with SH were included. Mean ± SD age was 38.8 ± 14.2 years and 75.9% were women. Diagnosis was PHEO in 35 patients (42.2%), aldosteronoma (APA) in 28 (33.7%), cortisol producing adenoma (CPA) in 16 (19.3%), and ACTH-dependent Cushing's in 4 (4.8%). Laparoscopic adrenalectomy was performed in 81 (97.6%) patients. Mean ± SD follow-up was 57.4 ± 49.6 months (range 1-232). Surgical morbidity occurred in 7.2% of patients and there was no mortality. Remission of SH occurred in 61(73.5%): 100% of ACTH-dependent Cushing's, 85.7% of PHEO, 68.8% of CPA, and 57.1% of APA. Biochemical phenotype and the combination of larger tumor size, number of antihypertensive drugs, male gender, older age, obesity, and preoperative SH for more than 5 years were associated with less likely clinical remission in patients with APA (p = 0.004), CPA (p < 0.0001), and PHEO (p < 0.0001).
CONCLUSION: SH remission rates are 57-100% after adrenalectomy. Several prognostic factors could be used to predict SH control. Adrenalectomy provides good clinical outcome and must be considered a treatment option in all surgical candidates.

Entities:  

Keywords:  Adrenal tumors; Adrenalectomy; Cushing’s; Hypertension; Pheochromocytoma

Year:  2021        PMID: 34159439     DOI: 10.1007/s00423-021-02245-2

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  23 in total

1.  Impact and timing of bilateral adrenalectomy for refractory adrenocorticotropic hormone-dependent Cushing’s syndrome.

Authors:  Lilah F Morris; Rachel S Harris; Denái R Milton; Steven G Waguespack; Mouhammed A Habra; Camilo Jimenez; Rena Vassilopoulou-Sellin; Jeffrey E Lee; Nancy D Perrier; Elizabeth G Grubbs
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

Review 2.  Pheochromocytoma and Paraganglioma.

Authors:  Hartmut P H Neumann; William F Young; Charis Eng
Journal:  N Engl J Med       Date:  2019-08-08       Impact factor: 91.245

3.  Clinical and pathological data of 10 malignant pheochromocytomas: long-term follow up in a single institute.

Authors:  Kuo-How Huang; Shiu-Dong Chung; Shyh-Chyan Chen; Shih-Chieh Chueh; Yeong-Shiau Pu; Ming-Kuen Lai; Wei-Chou Lin
Journal:  Int J Urol       Date:  2007-03       Impact factor: 3.369

Review 4.  Primary aldosteronism. Results of surgical treatment.

Authors:  C Y Lo; P C Tam; A W Kung; K S Lam; J Wong
Journal:  Ann Surg       Date:  1996-08       Impact factor: 12.969

5.  Outcomes analysis in patients undergoing laparoscopic adrenalectomy for hormonally active adrenal tumors.

Authors:  L M Brunt; J F Moley; G M Doherty; T C Lairmore; M K DeBenedetti; M A Quasebarth
Journal:  Surgery       Date:  2001-10       Impact factor: 3.982

6.  Surgical treatment of primary hyperaldosteronism.

Authors:  R J Weigel; S A Wells; J C Gunnells; G S Leight
Journal:  Ann Surg       Date:  1994-04       Impact factor: 12.969

Review 7.  Primary aldosteronism.

Authors:  Sean M Wrenn; Anand Vaidya; Carrie C Lubitz
Journal:  Gland Surg       Date:  2020-02

8.  [Consensus on Systemic Arterial Hypertension In México].

Authors:  Martín Rosas-Peralta; Silvia Palomo-Piñón; Gabriela Borrayo-Sánchez; Alejandra Madrid-Miller; Eduardo Almeida-Gutiérrez; Héctor Galván-Oseguera; José Antonio Magaña-Serrano; Guillermo Saturno-Chiu; Erick Ramírez-Arias; Efrén Santos-Martínez; Enrique Díaz-Díaz; Selene Janette Salgado-Pastor; Gerardo Morales-Mora; Luz Elena Medina-Concebida; Oliva Mejía-Rodríguez; Claudia Elsa Pérez-Ruiz; Luis Raúl Chapa-Mejía; Cleto Álvarez-Aguilar; Gilberto Pérez-Rodríguez; María Guadalupe Castro-Martínez; Joaquín López-Bárcena; José Ramón Paniagua-Sierra
Journal:  Rev Med Inst Mex Seguro Soc       Date:  2016

9.  Endocrine hypertension: An overview on the current etiopathogenesis and management options.

Authors:  Reena M Thomas; Ewa Ruel; Prapimporn Ch Shantavasinkul; Leonor Corsino
Journal:  World J Hypertens       Date:  2015

10.  Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center.

Authors:  Henrik Falhammar; Magnus Kjellman; Jan Calissendorff
Journal:  Endocrine       Date:  2018-09-15       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.